Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 76.04 USD -4.16% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Transmedics Group Inc?
Write Note

Transmedics Group Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Transmedics Group Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Transmedics Group Inc
NASDAQ:TMDX
Operating Expenses
-$206.5m
CAGR 3-Years
-57%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Operating Expenses
-$6.3B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
-9%
Boston Scientific Corp
NYSE:BSX
Operating Expenses
-$8.1B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Stryker Corp
NYSE:SYK
Operating Expenses
-$9.2B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
Abbott Laboratories
NYSE:ABT
Operating Expenses
-$16B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Expenses
-$3.2B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-14%
No Stocks Found

Transmedics Group Inc
Glance View

Market Cap
2.6B USD
Industry
Health Care

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 148 full-time employees. The company went IPO on 2019-05-02. The company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.

TMDX Intrinsic Value
45.97 USD
Overvaluation 40%
Intrinsic Value
Price

See Also

What is Transmedics Group Inc's Operating Expenses?
Operating Expenses
-206.5m USD

Based on the financial report for Sep 30, 2024, Transmedics Group Inc's Operating Expenses amounts to -206.5m USD.

What is Transmedics Group Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-40%

Over the last year, the Operating Expenses growth was -27%. The average annual Operating Expenses growth rates for Transmedics Group Inc have been -57% over the past three years , -40% over the past five years .

Back to Top